Teacher Retirement System of Texas acquired a new stake in shares of Aerie Pharmaceuticals Inc (NASDAQ:AERI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,334 shares of the company’s stock, valued at approximately $617,000.
A number of other institutional investors have also recently made changes to their positions in the business. Alps Advisors Inc. lifted its position in Aerie Pharmaceuticals by 13.6% during the fourth quarter. Alps Advisors Inc. now owns 40,673 shares of the company’s stock valued at $2,430,000 after buying an additional 4,883 shares during the period. American Century Companies Inc. lifted its position in Aerie Pharmaceuticals by 38.6% during the fourth quarter. American Century Companies Inc. now owns 33,588 shares of the company’s stock valued at $2,007,000 after buying an additional 9,352 shares during the period. Public Employees Retirement Association of Colorado purchased a new position in Aerie Pharmaceuticals during the fourth quarter valued at $176,000. Moody Aldrich Partners LLC lifted its position in Aerie Pharmaceuticals by 48.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 31,956 shares of the company’s stock valued at $1,909,000 after buying an additional 10,430 shares during the period. Finally, Rice Hall James & Associates LLC lifted its position in Aerie Pharmaceuticals by 14.4% during the fourth quarter. Rice Hall James & Associates LLC now owns 269,161 shares of the company’s stock valued at $16,082,000 after buying an additional 33,927 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.
Aerie Pharmaceuticals stock traded down $1.85 on Monday, hitting $56.10. The stock had a trading volume of 176,413 shares, compared to its average volume of 366,277. The company has a current ratio of 10.09, a quick ratio of 10.09 and a debt-to-equity ratio of 0.91. The stock has a market cap of $2,288.61, a price-to-earnings ratio of -13.91 and a beta of 0.98. Aerie Pharmaceuticals Inc has a 12-month low of $38.14 and a 12-month high of $66.60.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($1.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.21) by ($0.17). equities analysts anticipate that Aerie Pharmaceuticals Inc will post -3.62 EPS for the current fiscal year.
Several equities analysts have commented on AERI shares. Zacks Investment Research lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, November 22nd. Mizuho reissued a “buy” rating and set a $87.00 price objective on shares of Aerie Pharmaceuticals in a research report on Tuesday, December 19th. Canaccord Genuity set a $73.00 price objective on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, December 18th. BidaskClub lowered Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, January 11th. Finally, Cantor Fitzgerald set a $77.00 price target on Aerie Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, December 18th. Three analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $78.75.
TRADEMARK VIOLATION WARNING: This news story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/19/teacher-retirement-system-of-texas-invests-617000-in-aerie-pharmaceuticals-inc-aeri.html.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.